438PD Improved time to quality of life deterioration in patients with progressive midgut neuroendocrine tumors treated with 177Lu-DOTATATE: The NETTER-1 phase III trial
Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum R, Kunz P, Hobday T, Hendifar A, Öberg K, Sierra M, Ruszniewski P, Krenning E. 438PD Improved time to quality of life deterioration in patients with progressive midgut neuroendocrine tumors treated with 177Lu-DOTATATE: The NETTER-1 phase III trial. Annals Of Oncology 2017, 28: v146. DOI: 10.1093/annonc/mdx368.010.Peer-Reviewed Original Research